Clinical and microbiological rationale for the use of a herbal preparation in children with rhinopharyngitis

Abstract

Introduction. The work includes the results of clinical and microbiological studies that determine the feasibility of using the herbal preparation EPS® 7630 for the treatment of rhinopharyngitis (RF) in children. The introduction provides a brief review of the literature data on the role of the microbial factor and the important contribution of dysbiotic disorders of the URT microflora in the development of the Russian Federation. The porpose of persistent properties of opportunistic microorganisms (UPM) is outlined: the ability to biofilm formation – BPO and inactivation of lysozyme – ALA as dysbiotic markers of RF, which create conditions for relapses and chronicity of the disease, reduce the effectiveness of antimicrobial therapy. Goal.The aim of the work was the clinical and microbiological substantiation of the effectiveness of using EPS® 7630 in the treatment of RF in children.Materials and methods. The study involved 79 children aged 3 to 15 years. 1st group – 43 children who received treatment, including, along with traditional treatment, the drug Umckalor EPS® 7630, 2nd group (comparison) – 36 children who did not receive the tested drug. Microbiological examination was carried out by taking swabs from the pharynx and nose before and after treatment; BPO and ALA were determined according to the methods of Bukharin O.V. et al. (1999).Results. Conducted clinical studies have established a reduction in the timing of relief of the main symptoms of RF (cough, rhinitis, sore throat, fever) in children treated with EPS® 7630 compared to the comparison group. Microbiological studies of microorganisms isolated from the nasopharynx of children with RF revealed the ability of EPS® 7630 to suppress bacterial persistence factors (BPO and ALA) by 60% or more from the initial level.Conclusions. The data obtained reveal one of the mechanisms of the antimicrobial action of EPS® 7630, which consists in suppressing the persistent potential of UPM and regulating the effect of the drug on the microbiocenosis of the URT. The clinical and microbiological efficacy of using EPS® 7630 in the treatment of RF in children has been proven.